Background: Androgen deprivation therapy (ADT) is the cornerstone treatment of prostate cancer. However, androgen independent status inevitably develops over time, leading to the castration resistant prostate cancer (CRPC) phenotype. Several treatments, including chemotherapy agents and novel hormonal agents, have been shown to improve outcome of patients with metastatic CRPC (mCRPC). Recently, two randomized controlled trials (RCT) demonstrated increased metastasis free survival (MFS) with apalutamide (SPARTAN Trial) and enzalutamide (PROSPER Trial) in nmCRPC patients, but failed to demonstrate a statistically significant increase in overall survival (OS). Methods: A meta-analysis at trial level was performed including published data from SPARTAN and PROSPER trials. Efficacy data was investigated and retrieved to calculate hazard-ratio (HR) for OS and MFS, with 95% CI. The safety profile was investigated for fatal adverse events (FAEs) and the relative risk (RR) calculated, with 95% CI. Random-effects or fixed-effects models were performed on the basis of the heterogeneity of included studies. A p-value <0.05 was considered statistically significant. Results: A total of 2,602 patients were included for efficacy (intention-to-treat [ITT] population) and 2,596 for safety analysis (per-protocol population). 1736 patients received novel hormonal agents (806 apalutamide and 930 enzalutamide) and 866 placebo. Efficacy analysis confirmed improved MFS (HR 0.29; 95% CI, 0.25-0.33; p < 0.0001) and also demonstrated a significant increase in OS (HR 0.76; 95% CI, 0.59-0.76; p ¼ 0.03). Safety analysis showed an increased risk of FAEs (HR 5.24; 95% CI, 1.89-14.55) with apalutamide and enzalutamide, however this should be interpreted with caution due to the much longer exposure time to the experimental arm compared to placebo. Conclusions: This meta-analysis reinforces the benefit of MFS and demonstrated a significant increase in OS with novel hormonal agents apalutamide and enzalutamide in patients with nmCRPC. Further analysis will be necessary to determine the breakdown of treatment-related versus -unrelated deaths. Legal entity responsible for the study: Daniel Vargas Pivato de Almeida. Use of statins by prostate cancer pts has been associated with longer time to progression (TTP) during ADT in the hormone-sensitive setting (Harshman, JAMA Oncol 2015). Methods: We evaluated the impact of statin use in PFS and OS in mCRPC patients treated with cabazitaxel or mitoxantrone in the TROPIC phase III trial. Kaplan-Meier, univariable (UV) and multivariable (MV) cox-regression models were constructed to evaluate the association between use of statins and overall survival (OS), PSA progression-free survival (PSA-PFS) and radiographic PFS (rPFS). Covariates included in the multivariable model are listed in the table. Results: 755 pts were included in the analysis. 138 (18.6%) pts received statins: atorvastatin (53 pts, 38.4%), simvastatin (56 pts, 40.6%), rosuvastatin (14 pts, 10.1%), pravastatin (9 pts, 6.5%), lovastatin (4 pts, 2.9%) and fluvastatin (2 pts; 1.4%). 72 pts (52.2%) were allocated to the mitoxantrone arm and 66 pts (47.8%) to the cabazitaxel arm of the trial. Statin use was associated with longer median OS (15.8 vs 13.4m; HR: 0.74; p ¼ 0.01) but no difference in PSA-PFS (4.8 vs 4.6m; HR: 0.98; p ¼ 0.824) or rPFS (8.3 vs 7.2m; HR: 0.94; p ¼ 0.661) was observed. Statin use was associated with a longer time on prior hormone-therapy (5.3 vs 3.7 yrs; p < 0.001). In MV cox-regression models, the impact of statin use in survival was independent of treatment arm (cabazitaxel vs mitoxantrone) and other prognostic factors (Table) .
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Results: 755 pts were included in the analysis. 138 (18.6%) pts received statins: atorvastatin (53 pts, 38.4%), simvastatin (56 pts, 40.6%), rosuvastatin (14 pts, 10.1%), pravastatin (9 pts, 6.5%), lovastatin (4 pts, 2.9%) and fluvastatin (2 pts; 1.4%). 72 pts (52.2%) were allocated to the mitoxantrone arm and 66 pts (47.8%) to the cabazitaxel arm of the trial. Statin use was associated with longer median OS (15.8 vs 13.4m; HR: 0.74; p ¼ 0.01) but no difference in PSA-PFS (4.8 vs 4.6m; HR: 0.98; p ¼ 0.824) or rPFS (8.3 vs 7.2m; HR: 0.94; p ¼ 0.661) was observed. Statin use was associated with a longer time on prior hormone-therapy (5.3 vs 3.7 yrs; p < 0.001). In MV cox-regression models, the impact of statin use in survival was independent of treatment arm (cabazitaxel vs mitoxantrone) and other prognostic factors (Table) . Background: Subset analysis of trials investigating taxanes in patients with mCRPC suggest an association between Grade 3 NP and disease outcomes. In the Phase 3 PROSELICA trial (NCT01308580), NP was more common in patients receiving cabazitaxel 25 mg/m 2 (C25) vs cabazitaxel 20 mg/m 2 (C20) -73% vs 42%, respectively. Post hoc analyses of PROSELICA examined the relationship between incidence of NP, survival and response. Methods: PROSELICA assessed the non-inferiority of C20 (n ¼ 598) vs C25 (n ¼ 602) in terms of overall survival (OS) in men with mCRPC. Prophylactic granulocyte colony-stimulating factor was given to patients with Grade 3 NP. OS and progressionfree survival (PFS) were analyzed using Kaplan-Meier (KM) estimates and Cox proportional hazard models. Nominal p values were determined by log-rank tests. Prostatespecific antigen response rate (PSArr; defined as proportion of patients with a > 50 % PSA decline from baseline) was analyzed in the eligible population using KM estimates with Chi 2 tests and odds ratios. OS, PFS and PSArr were correlated with Grade 3 NP occurrence and baseline neutrophilia (neutrophils 7000 G/l) by univariate analysis. Results: In the intent-to-treat (ITT) population, development of Grade 3 NP was associated with better PSArr, PFS and OS (p < 0.001; Table) . The positive association was observed in both treatment arms and in poor-risk patients with baseline neutrophilia. 
